PFE Announces Positive Topline Phase 3 Results for LITFULO in Patients with Nonsegmental Vitiligo

more on PFE Pfizer Reports Positive Phase 3 Results for LITFULO in Vitiligo ⠀ • Two Phase 3 studies met their co-primary endpoints, with LITFULO showing statistically significant improvements in facial and total body repigmentation versus placebo at Week 52. • No new safety signals were observed, and the safety profile was consistent with previous studies in alopecia areata. • Pfizer plans to submit global regulatory filings for LITFULO as a potential oral treatment for adults with nonsegmental vitiligo.